The global burden of yellow fever.


Journal

eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614

Informations de publication

Date de publication:
16 03 2021
Historique:
received: 06 11 2020
accepted: 23 02 2021
entrez: 16 3 2021
pubmed: 17 3 2021
medline: 26 8 2021
Statut: epublish

Résumé

Yellow fever (YF) is a viral, vector-borne, haemorrhagic fever endemic in tropical regions of Africa and South America. The vaccine for YF is considered safe and effective, but intervention strategies need to be optimised; one of the tools for this is mathematical modelling. We refine and expand an existing modelling framework for Africa to account for transmission in South America. We fit to YF occurrence and serology data. We then estimate the subnational forces of infection for the entire endemic region. Finally, using demographic and vaccination data, we examine the impact of vaccination activities. We estimate that there were 109,000 (95% credible interval [CrI] [67,000-173,000]) severe infections and 51,000 (95% CrI [31,000-82,000]) deaths due to YF in Africa and South America in 2018. We find that mass vaccination activities in Africa reduced deaths by 47% (95% CrI [10%-77%]). This methodology allows us to evaluate the effectiveness of vaccination and illustrates the need for continued vigilance and surveillance of YF.

Identifiants

pubmed: 33722340
doi: 10.7554/eLife.64670
pii: 64670
pmc: PMC7963473
doi:
pii:

Substances chimiques

Yellow Fever Vaccine 0

Banques de données

Dryad
['10.5061/dryad.47v3c']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : World Health Organization
ID : 001
Pays : International
Organisme : Medical Research Council
ID : MR/R015600/1
Pays : United Kingdom
Organisme : Bill and Melinda Gates Foundation
ID : OPP1117543

Informations de copyright

© 2021, Gaythorpe et al.

Déclaration de conflit d'intérêts

KG, AH, KJ, DG, LC, TG, NF No competing interests declared

Références

Wkly Epidemiol Rec. ;92(16):193-204
pubmed: 28429585
Elife. 2015 Jun 30;4:e08347
pubmed: 26126267
Bull Soc Pathol Exot Filiales. 1986;79(2):199-206
pubmed: 3731366
Sci Rep. 2017 Jul 7;7(1):4848
pubmed: 28687779
Ann Soc Belg Med Trop. 1985;65(1):91-3
pubmed: 4004378
MMWR Morb Mortal Wkly Rep. 2015 Jun 19;64(23):647-50
pubmed: 26086636
Clin Microbiol Infect. 2018 Sep;24(9):1019.e1-1019.e4
pubmed: 29427798
MMWR Morb Mortal Wkly Rep. 2017 May 05;66(17):457-459
pubmed: 28472025
J Clin Virol. 2015 Mar;64:160-73
pubmed: 25453327
PLoS Negl Trop Dis. 2014 Aug 07;8(8):e3048
pubmed: 25102306
Trop Med Health. 2017 Nov 2;45:35
pubmed: 29118655
Am J Trop Med Hyg. 2016 Dec 7;95(6):1435-1439
pubmed: 27928091
Am J Trop Med Hyg. 2006 Jun;74(6):1078-83
pubmed: 16760524
Elife. 2020 Jul 28;9:
pubmed: 32718436
PLoS Comput Biol. 2019 Sep 23;15(9):e1007355
pubmed: 31545790
PLoS Negl Trop Dis. 2020 May 7;14(5):e0008304
pubmed: 32379756
Trans R Soc Trop Med Hyg. 2014 Aug;108(8):482-7
pubmed: 24980556
Lancet Glob Health. 2018 Mar;6(3):e270-e278
pubmed: 29398634
Clin Infect Dis. 2019 May 2;68(10):1761-1762
pubmed: 30204852
Comp Immunol Microbiol Infect Dis. 1990;13(2):95-100
pubmed: 2208973
Mem Inst Oswaldo Cruz. 2018 Sep 03;113(10):e180278
pubmed: 30427974
Hum Vaccin Immunother. 2015;11(9):2183-7
pubmed: 26090855
Bull Soc Pathol Exot. 1999 Dec;92(5):333-6
pubmed: 10690471
Epidemiol Infect. 2019 Nov 11;147:e299
pubmed: 31709961
Rev Soc Bras Med Trop. 2011 May-Jun;44(3):297-9
pubmed: 21537794
PLoS Negl Trop Dis. 2021 Jan 11;15(1):e0008974
pubmed: 33428623
Lancet Infect Dis. 2019 Dec;19(12):1363-1370
pubmed: 31543249
Parasit Vectors. 2014 Jul 22;7:338
pubmed: 25052008
Sci Data. 2015 Jul 07;2:150035
pubmed: 26175912
Bull World Health Organ. 1987;65(6):855-60
pubmed: 3501739
PLoS Med. 2014 May 06;11(5):e1001638
pubmed: 24800812
Expert Rev Vaccines. 2005 Aug;4(4):553-74
pubmed: 16117712
PLoS Negl Trop Dis. 2017 Apr 27;11(4):e0005568
pubmed: 28448507
Virol J. 2019 May 17;16(1):65
pubmed: 31101058
J Infect Dis. 2020 Jun 11;221(12):1922-1924
pubmed: 31545366

Auteurs

Katy Am Gaythorpe (KA)

WHO Collaborating Centre for Infectious Disease Modelling, MRC Centre for Global Infectious Disease Analysis, Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), Imperial College London, London, United Kingdom.

Arran Hamlet (A)

WHO Collaborating Centre for Infectious Disease Modelling, MRC Centre for Global Infectious Disease Analysis, Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), Imperial College London, London, United Kingdom.

Kévin Jean (K)

Maître de conférences, Laboratoire MESuRS - Cnam Paris, Paris, France.

Daniel Garkauskas Ramos (D)

Secretariat for Health Surveillance, Brazilian Ministry of Health, Brasilia, Brazil.

Laurence Cibrelus (L)

World Health Organisation, Geneva, Switzerland.

Tini Garske (T)

WHO Collaborating Centre for Infectious Disease Modelling, MRC Centre for Global Infectious Disease Analysis, Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), Imperial College London, London, United Kingdom.

Neil Ferguson (N)

WHO Collaborating Centre for Infectious Disease Modelling, MRC Centre for Global Infectious Disease Analysis, Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), Imperial College London, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH